Synlogic News Releases https://investor.synlogictx.com/ Synlogic News Releases en Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors https://investor.synlogictx.com/news-releases/news-release-details/synlogic-announces-clinical-collaboration-evaluate-synb1891 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 22, 2019-- Synlogic, Inc. , (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore Synlogic’s Synthetic Wed, 22 May 2019 07:00:00 -0400 Synlogic News Releases 8516 Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update https://investor.synlogictx.com/news-releases/news-release-details/synlogic-reports-first-quarter-2019-financial-results-and – Company will host a conference call and webcast at 5:00 pm ET today – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial Thu, 09 May 2019 16:02:00 -0400 Synlogic News Releases 8496 Synlogic Announces First Quarter 2019 Conference Call and Webcast https://investor.synlogictx.com/news-releases/news-release-details/synlogic-announces-first-quarter-2019-conference-call-and CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2019 financial results after the market Thu, 02 May 2019 16:05:00 -0400 Synlogic News Releases 8481 Synlogic Presents Data Describing a Solid Oral Formulation Process for Synthetic Biotic™ Medicine SYNB1618 for the Treatment of PKU at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) https://investor.synlogictx.com/news-releases/news-release-details/synlogic-presents-data-describing-solid-oral-formulation-process - Synlogic’s robust and reproducible lyophilization process provides a solid formulation of SYNB1618 with improved quality attributes, stability and minimal loss of viability compared to liquid formulation - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2019-- Synlogic, Inc. Tue, 30 Apr 2019 07:00:00 -0400 Synlogic News Releases 8466 Synlogic to Present Data from New Solid Oral Formulation Process at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) https://investor.synlogictx.com/news-releases/news-release-details/synlogic-present-data-new-solid-oral-formulation-process-22nd CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 15, 2019-- Synlogic, Inc. , (Nasdaq: SYBX) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that data from its program to develop solid oral formulations of Mon, 15 Apr 2019 16:10:00 -0400 Synlogic News Releases 8431 Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer https://investor.synlogictx.com/news-releases/news-release-details/synlogic-appoints-scott-plevy-md-chief-scientific-officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 9, 2019-- Synlogic, Inc . (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Scott Plevy , M.D., as Chief Scientific Officer. Dr. Tue, 09 Apr 2019 07:00:00 -0400 Synlogic News Releases 8386 Synlogic to Webcast Presentation at the 18th Annual Needham Healthcare Conference https://investor.synlogictx.com/news-releases/news-release-details/synlogic-webcast-presentation-18th-annual-needham-healthcare CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2019-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 18th Annual Needham Healthcare Conference at 3:30 pm ET on Tuesday, April 9, 2019 , in Tue, 02 Apr 2019 16:05:00 -0400 Synlogic News Releases 8381 Synlogic to Webcast Presentation at the Oppenheimer 29th Annual Healthcare Conference https://investor.synlogictx.com/news-releases/news-release-details/synlogic-webcast-presentation-oppenheimer-29th-annual-healthcare CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 13, 2019-- Synlogic (Nasdaq:SYBX) announced today that Caroline Kurtz , Ph.D., Synlogic’s Head of Metabolism, will provide a corporate update at Oppenheimer’s 29th Annual Healthcare Conference at 3:20 pm ET on Wednesday, March 20, 2019 , in New York City . Wed, 13 Mar 2019 16:05:00 -0400 Synlogic News Releases 8371 Synlogic Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update https://investor.synlogictx.com/news-releases/news-release-details/synlogic-reports-fourth-quarter-and-full-year-2018-financial – Ended 2018 with approximately $123 million in cash and investments, which provides runway through 2020 – – Clinical trial readouts expected in mid-2019 from two Synthetic Biotic ™ medicines and first IND application expected from Synlogic’s immuno-oncology platform in second half of 2019 – – Tue, 12 Mar 2019 07:00:00 -0400 Synlogic News Releases 8351 Synlogic Announces Achievement of Milestone in Collaboration to Develop Synthetic Biotic™ Medicines to Treat Inflammatory Bowel Disease https://investor.synlogictx.com/news-releases/news-release-details/synlogic-announces-achievement-milestone-collaboration-develop CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2019-- Synlogic, Inc ., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the advancement of Synthetic Biotic medicines to the lead optimization stage in its Wed, 06 Mar 2019 07:00:00 -0500 Synlogic News Releases 8331